# Lantheus Holdings, Inc.  Share Price Target ‘$133.92’, now 41.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/lantheus-holdings-inc-share-price-target-133-92-now-41-2-upside-potential/4121188014
- Published: 2025-03-05T13:33:56+00:00
- Author: Charlotte Edwards

**Lantheus Holdings, Inc.** which can be found using ticker (LNTH) have now 13 market
analysts covering the stock. The analyst consensus now points to a rating of ‘strong_buy’.
The target price High/Low ranges between $166.00 and $110.00 calculating the average
target share price we see $133.92. (at the time of writing). Given that the stocks
previous close was at $94.86 and the analysts are correct then there would likely
be a percentage uptick in value of 41.2%. It’s also worth noting that there is a
50 day moving average of $90.16 and the 200 moving average now moves to $95.28. 
The total market capitalization for the company now stands at 6.72B. The price for
the stock stands currently at: $98.17 USD

 The potential market cap would be $9,490,591,237 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 22.52, revenue per share of $22.17
and a 15.35% return on assets.

Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted
therapeutics, and artificial intelligence solutions to find, fight and follow serious
medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical
oncology, and strategic partnerships. Its precision diagnostic products assist healthcare
professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical
oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its
strategic partnerships focus on enabling precision medicine through the use of biomarkers,
digital solutions and pharma services platforms, and also includes the Company’s
license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products
are used by oncologists, urologists, nuclear medicine physicians, cardiologists,
sonographers, technologists, radiologists, and internal medicine physicians working
in a variety of clinical settings.

Share on:
